{
    "clinical_study": {
        "@rank": "92539", 
        "arm_group": [
            {
                "arm_group_label": "Asenapine Sublingual Tablets", 
                "arm_group_type": "Experimental", 
                "description": "Asenapine Sublingual Tablets, 10 mg. Twice daily for a period of 7 days"
            }, 
            {
                "arm_group_label": "Saphris Subligual Tablets", 
                "arm_group_type": "Active Comparator", 
                "description": "Asenapine Sublingual Tablets, 10 mg. Twice daily for 2 periods of 7 days each."
            }
        ], 
        "brief_summary": {
            "textblock": "To compare and evaluate the oral bioavailability of Asenapine Sublingual Tablets, 10 mg\n      manufactured by AMNEAL PHARMACEUTICALS, USA with SAPHRIS\u00ae (asenapine) sublingual tablets, 10\n      mg."
        }, 
        "brief_title": "Bioequivalence Fasting Study in Patients", 
        "completion_date": {
            "#text": "June 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Schizophrenia", 
        "condition_browse": {
            "mesh_term": "Schizophrenia"
        }, 
        "detailed_description": {
            "textblock": "To compare and evaluate the oral bioavailability of Asenapine Sublingual Tablets, 10 mg\n      manufactured by AMNEAL PHARMACEUTICALS, USA with SAPHRIS\u00ae (asenapine) sublingual tablets, 10\n      mg following a multiple-dose administration in adult human patients who are receiving a\n      stable twice daily dose of asenapine maleate EQ 10 mg base.\n\n      To monitor the safety and tolerability of a multiple doses of asenapine sublingual tablets\n      10 mg in adult human patients who are receiving a stable twice daily dose of asenapine\n      maleate EQ 10 mg base."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Adult patients of either sex with age between 18 to 65 years (both inclusive) and\n             have been taking a stable dose of asenapine maleate sublingual tablet, EQ 10 mg base\n             twice daily therapy for at least three months.\n\n          -  Willing and able to comply with study visit schedule and other protocol requirements\n             as indicated by signed written informed consent witnessed by a legally acceptable\n             representative.\n\n          -  Females of childbearing (who has not completed 01 year after menopause & have not\n             gone through hysterectomy or bilateral tubal ligation) potential must have a negative\n             pregnancy test (at screening, before randomization and before check-in to housing) as\n             well as must be non-lactating at screening and must agree to use an effective\n             contraceptive method during study.\n\n        Exclusion Criteria:\n\n          -  History of allergic or adverse reactions to asenapine maleate or olanzapine as judged\n             by investigator\n\n          -  If consuming tobacco orally (spit tobacco, gutka, pan masala, pan, etc.)\n\n          -  A history of severe hepatic impairment, drug induced leukopenia/ neutropenia,\n             congenital prolongation of the QT interval, cardiac arrhythmias, myocardial\n             infarction or unstable heart disease\n\n          -  Concurrent primary psychiatric or neurological diagnosis, including organic mental\n             disorder, severe tardive dyskinesia, or idiopathic Parkinson's disease\n\n          -  Abnormal laboratory results\n\n          -  A history of granulocytopenia or myeloproliferative disorders (drug-induced or\n             idiopathic)\n\n          -  A medical or surgical condition that might interfere with the absorption, metabolism,\n             or excretion of asenapine maleate\n\n          -  History of multiple syncopal episodes\n\n          -  History of epilepsy or risk for seizures\n\n          -  Any condition/ Abnormal baseline findings that in the investigators' judgment might\n             increase the risk to the patient (e.g. Significant orthostatic hypotension defined as\n             a drop in systolic blood pressure of 30 mm Hg or more and/or a drop in diastolic\n             blood pressure of 20 mm Hg or more on standing) or decrease the chance of obtaining\n             satisfactory data needed to obtain the objective of the study.\n\n          -  A history of alcohol or drug dependence by DSM-IV criteria during the 6-month period\n             immediately prior to study entry\n\n          -  Positive tests for drug or alcohol abuse at screening or baseline\n\n          -  Use of any of the following medication in the 14 days preceding enrollment: Strong\n             CYP3A4 inhibitors, Strong CYP3A4 inducers, CYP1A2 inhibitors, Antihypertensive\n             medication or any medication that might predispose to orthostatic hypotension, Drugs\n             known to suppress bone marrow function, medications known to prolong the QTc\n             interval.\n\n          -  Participation in any other clinical study or receipt of treatment with any\n             investigational drug or device within 1 month prior Screening.\n\n          -  Blood donation/ loss exceeding 550 mL within last 90 days.\n\n          -  Any expected changes in concomitant medications during the period of study\n\n          -  Compliance with outpatient medication schedule not expected"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "65 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "48", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "February 25, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02072954", 
            "org_study_id": "ARL/CT/13/003", 
            "secondary_id": "CTRI No. CTRI/2013/11/004152"
        }, 
        "intervention": [
            {
                "arm_group_label": "Asenapine Sublingual Tablets", 
                "description": "White to off-white, round, uncoated,unscored, flat-faced radius edge tablet. Debossed with A on one side and 17 on the other side", 
                "intervention_name": "Asenapine Sublingual Tablets 10 mg", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Saphris Subligual Tablets", 
                "description": "Round, white to off-white sublingual tablets, with \"10\" on one side within a circle", 
                "intervention_name": "Asenapine Sublingual Tablets 10 mg", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Asenapine"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "April 28, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Ahmedabad", 
                        "country": "India", 
                        "state": "Gujurat"
                    }, 
                    "name": "AMC MET Medical College and Sheth L. G Hospital"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Junagadh", 
                        "country": "India", 
                        "state": "Gujurat", 
                        "zip": "362 001"
                    }, 
                    "name": "Shri Hatkesh Healthcare Foundation"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Surat", 
                        "country": "India", 
                        "state": "Gujurat", 
                        "zip": "395 001"
                    }, 
                    "name": "Divyam Hospital"
                }
            }
        ], 
        "location_countries": {
            "country": "India"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Multicentric, Open Label, Randomized, Balanced, Two Treatment, Three Period, Three Sequence, Crossover, Multiple Dose, Steady State Bioequivalence Study of Asenapine Sublingual Tablets, 10 mg Manufactured by AMNEAL PHARMACEUTICALS, USA With Reference Product SAPHRIS\u00ae (Asenapine) Sublingual Tablets, 10 mg Manufactured by Catalent UK Swindon Zydis Ltd., Blagrove, Swindon, Wiltshire, SN5 8RU, UK; Distributed by Merck Sharp & Dohme Corp., a Subsidiary of Merck & Co., Inc., Whitehouse Station, NJ, 08889, USA in Adult Human Male & Female Patients Under Fasting Condition.", 
        "overall_official": {
            "affiliation": "Accutest Reserach laboratories (i) Pvt. Ltd.", 
            "last_name": "Ashutosh Jani, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": "India: Ministry of Health", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2/Phase 3", 
        "primary_completion_date": {
            "#text": "May 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "description": "The area under plasma concentration versus time curve, over the steady state dosing interval, calculated using linear trapezoidal method.", 
                "measure": "AUC 0-tau", 
                "safety_issue": "No", 
                "time_frame": "Dosing interval on day 7"
            }, 
            {
                "description": "Maximum measured plasma concentration over the steady state doing interval", 
                "measure": "Cmax", 
                "safety_issue": "No", 
                "time_frame": "Dosing interval on day 7"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02072954"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Minimum measured plasma concentration over the steady state dosing interval", 
                "measure": "Cmin", 
                "safety_issue": "No", 
                "time_frame": "Dosing interval on day 7"
            }, 
            {
                "description": "Time the maximum measured plasma concentration over the steady state dosing interval", 
                "measure": "Tmax", 
                "safety_issue": "No", 
                "time_frame": "Dosing interval on day 7"
            }, 
            {
                "description": "Average calculated plasma concentration over the steady state dosing interval", 
                "measure": "Cavg", 
                "safety_issue": "No", 
                "time_frame": "Dosing interval on day 7"
            }, 
            {
                "description": "[Cmax - Cmin/ Cavg] x 100", 
                "measure": "Percentage Fluctuation", 
                "safety_issue": "No", 
                "time_frame": "Dosing interval on day 7"
            }
        ], 
        "source": "Amneal Pharmaceuticals, LLC", 
        "sponsors": {
            "collaborator": {
                "agency": "Accutest Research Laboratories (I) Pvt. Ltd.", 
                "agency_class": "Industry"
            }, 
            "lead_sponsor": {
                "agency": "Amneal Pharmaceuticals, LLC", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "November 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}